NewAmsterdam Pharma Company NAMS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -1,002.9%-616pp | -386.9%+912pp | -1,298.6%-1,295pp | -3.5%— | |
| Net margin | -905.7%-375pp | -530.3%+726pp | -1,255.8%-1,234pp | -22%— | |
| Returns | |||||
| Return on equity | -28.3%+17.9pp | -46.2%+3.1pp | -49.3%— | —— | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0.1×0.0× | 0×— | —— | |
| Liquidity | |||||
| Current ratio | 7.9×-0.2× | 8.1×+1.1× | 7×-6.3× | 13.3×— | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Valuation | |||||
| Market capitalization | $3.98B+44.6% | $2.75B+174% | $1.01B+2.5% | $980.85M+11.8% | |
| Price / sales | 176.8×+116× | 60.4×-11.0× | 71.3×+61.8× | 9.6×— | |
| Price / book | 5.8×+2.2× | 3.6×+0.1× | 3.5×+1.2× | 2.3×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do NewAmsterdam Pharma Company's ratios come from?
- Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.